Search This Blog

Monday, June 15, 2026

Elicio Phase 2 miss, post-hoc survival benefit in pancreatic cancer, refines Phase 3

 

Elicio details Phase 2 AMPLIFY-7P miss and post-hoc disease-free survival benefit in fully resected (R0) patients, refines Phase 3

  • Refined Phase 3 program will evaluate ELI-002 7P in fully resected (R0) adjuvant pancreatic cancer patients.
  • Elicio guides that existing cash resources will fund operations into the fourth quarter of 2026.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)